Related Experiment Video
Updated: Dec 25, 2025
07:58
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
14.2K
Nucleobindin 2 expression is an independent prognostic factor for bladder cancer
Jeong Man Cho1, Kyong Tae Moon1, Ho Jung Lee2
1Department of Urology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
Medicine
|March 30, 2020
Summary
High Nucleobindin 2 (NUCB2) expression in urothelial carcinoma of the bladder (UCB) correlates with aggressive features and poorer patient survival. NUCB2 may be a biomarker for clinical outcomes and a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Nucleobindin 2 (NUCB2) is implicated in tumorigenesis and cancer progression.
- Understanding NUCB2's role in bladder cancer is crucial for clinical applications.
Purpose of the Study:
- To investigate the clinical significance of NUCB2 expression in urothelial carcinoma of the bladder (UCB).
- To evaluate NUCB2 as a potential biomarker for patient prognosis.
Main Methods:
- Immunohistochemistry was used to analyze NUCB2 expression in 225 UCB tissues.
- Kaplan-Meier analysis and Cox regression models assessed the correlation between NUCB2 expression and patient survival.
Main Results:
- High NUCB2 expression significantly correlated with aggressive clinicopathological features in UCB.
- Patients with high NUCB2 expression exhibited shorter overall and recurrence-free survival (P=.018 and P=.001).
Conclusions:
- Elevated NUCB2 expression is associated with aggressive UCB and predicts unfavorable prognosis.
- NUCB2 may serve as a feasible biomarker for clinical outcomes and a potential therapeutic target for UCB.
